Aztreonam/Avibactam Fills the Metallo-β-Lactamase Treatment Gap
This narrative review consolidates in vitro, pharmacokinetic, and phase III evidence positioning aztreonam/avibactam as the preferred agent for metallo-β-lactamase-producing Enterobacterales and clarifies why ceftazidime/avibactam plus aztreonam is not a pharmacokinetic equivalent.
📅 Journal publication: Dec 2026(online Sep 22, 2026)·Last updated: Oct 5, 2026
Aztreonam/Avibactam targets metallo-β-lactamase-producing bacteria, addressing a critical resistance challenge.
Multidrug-resistant Gram-negative bacteria, particularly those with metallo-β-lactamases (MBL), are a significant threat to global health, necessitating effective treatments like Aztreonam/Avibactam (AZA). AZA has been approved in China and the EU, exhibiting broad-spectrum activity against carbapenemase-producing Enterobacterales, but clinical data on MBL-producing infections remain limited. AZA presents a promising option for treating severe infections by multidrug-resistant Enterobacterales, but the clinical evidence for MBL-producing strains needs expansion to confirm its effectiveness. Aztreonam/Avibactam shows promise against carbapenemase-producing strains, but robust clinical evidence is needed for MBL-producing infections.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zhou J, Weng R, Ye Y, Han X, Hu H, Xu W, Shi Q, Wang Y, Huang W, Quan J, Zhang P, Fu Y, He J, Zhou Z, Du X, Zhao D, Jiang Y, Yu Y
Citation:Zhou J, Weng R, Ye Y, et al. Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam. Emerging microbes & infections. 2026;15(1):2732702. doi:10.1080/22221751.2026.2732702